Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: BBIO

BridgeBio Pharma, Inc.

Healthcare | Biotechnology

No licensed closing price on file for BBIO. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-3.57

BridgeBio Pharma, Inc. (NASDAQ: BBIO) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-19 09:29 UTC.

What BridgeBio Pharma, Inc. does

BridgeBio Pharma is a commercial-stage biopharmaceutical company that discovers, develops, and delivers medicines for patients with genetic diseases. The company operates a decentralized hub-and-spoke model designed to advance multiple programs simultaneously while managing capital efficiently. BridgeBio has obtained FDA approval for three products, with acoramidis (branded as Attruby) being its largest commercial product approved for transthyretin amyloid cardiomyopathy treatment in the United States.

Summarized from BridgeBio Pharma, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-3.57

Revenue, margins & earnings

FY2021: net loss $563M on revenue $70M$70MFY2021FY2022: net loss $481M on revenue $78M$78MFY2022FY2023: net loss $643M on revenue $9M$9MFY2023FY2024: net loss $536M on revenue $222M$222MFY2024FY2025: net loss $725M on revenue $502M$502MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →
Net income for FY2021, FY2022, FY2023, FY2024, FY2025 is the filer’s available-to-common figure (net of preferred dividends) — the filer tags no parent net income for those years.

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-21
  • 2026-09-21Chief Executive OfficerSale-8,721$601.9K
  • 2026-09-21Chief Executive OfficerSale-1,279$89.0K
  • 2026-08-20Chief Executive OfficerSale-100$8.6K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does BridgeBio Pharma, Inc. do?

BridgeBio Pharma is a commercial-stage biopharmaceutical company that discovers, develops, and delivers medicines for patients with genetic diseases.

When did BBIO last file with the SEC?

BridgeBio Pharma, Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-02. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-19 09:29 UTC. This page is also available as JSON at /api/data?ticker=BBIO and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for BBIO and 5,000+ tickers.

Create a free account — keep BBIO
For your agent
GET /api/data?ticker=BBIO

This page as JSON via rel="alternate" · REST API docs · MCP server (62 tools) · llms.txt